Altimmune Inc (ALT)

$3.86 -0.12 (-3.02%)
Market Cap 415.28M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 2,922,100
Avg Vol 3,691,306
Day's Range N/A - N/A
Shares Out 104.34M
Stochastic %K 2%
Beta -0.03
Analysts Strong Sell
Price Target $17.88

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
TTC1
TTC1 Dec. 27 at 9:52 AM
$ALT
0 · Reply
CentralizationC
CentralizationC Dec. 27 at 9:22 AM
$ALT Trading dynamics suggest reliability now matters more than momentum bursts. Efficiency gains must convert into measurable results. Credible progress tends to compress risk premiums. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Dec. 27 at 9:14 AM
$ALT
0 · Reply
Muskvoice
Muskvoice Dec. 27 at 8:35 AM
$ALT
0 · Reply
Guptasulo
Guptasulo Dec. 27 at 7:50 AM
$ALT Here is another article freely accessible; https://www.sciencedirect.com/science/article/pii/S0146280625002324 Supplements "Didioh $ALT nytimes.com/2025/12/21/heal... Check this out. It talks about discontinuation of glp-1’s due to side effects and muscle loss." Reason why people are abandoning GLP-1 (others) which ALT now satisfies with Muscle preservation+ Liver issues that it solves see below; "ImNotLion $ALT Annual deaths in the US from liver conditions: 60,000 - 70,000 Europe: 200,000 - 250,000..."
0 · Reply
ImNotLion
ImNotLion Dec. 27 at 7:10 AM
$ALT Annual deaths in the US from liver conditions: 60,000 - 70,000 Europe: 200,000 - 250,000 Safety, side effects and tolerance have been satisfied. This would seem to justify fast tracking Pemvidutide in both. The bureaucracy of approvals needs to address this life saving drug ASAP. Even 10% of that total would be like a city population of fatalities due to lengthy delays. Inexcusable!
0 · Reply
Wolf1971
Wolf1971 Dec. 27 at 5:34 AM
$ALT
0 · Reply
Didioh
Didioh Dec. 27 at 5:07 AM
$ALT https://www.nytimes.com/2025/12/21/health/older-people-glp1-weight.html?smid=nytcore-ios-share Check this out. It talks about discontinuation of glp-1’s due to side effects and muscle loss. Hello Pemvi.
3 · Reply
BuddyBoy6975
BuddyBoy6975 Dec. 27 at 4:47 AM
$ALT My question HERE is what news are THESE buyers seeing…?
0 · Reply
BuddyBoy6975
BuddyBoy6975 Dec. 27 at 4:22 AM
$ALT So my take on my time here WS obviously sees the Gi-NORMOUS future rev’s in Alt’s pipeline/pemvi So THEY (always banks) have been suppressing SP so their CO-PARTIES can toss low ball offers at them via BO But ALT has said FU, we’re not gonna sell you US @ $50/share. You can pound sand. And that’s where we are JMO
1 · Reply
Latest News on ALT
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dec 23, 2025, 7:42 PM EST - 3 days ago

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 12:57 PM EST - 7 days ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Dec 19, 2025, 11:37 AM EST - 7 days ago

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 7 days ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 7 days ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 25 days ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 4 weeks ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 5 weeks ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 6 weeks ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 6 weeks ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 7 weeks ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 7 weeks ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 7 weeks ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 7 weeks ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 7 weeks ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 2 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 2 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 3 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 3 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 3 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 3 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 4 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 4 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 4 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:44 PM EDT - 4 months ago

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 13, 2025, 2:57 PM EDT - 4 months ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Aug 12, 2025, 7:00 AM EDT - 4 months ago

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

TTC1
TTC1 Dec. 27 at 9:52 AM
$ALT
0 · Reply
CentralizationC
CentralizationC Dec. 27 at 9:22 AM
$ALT Trading dynamics suggest reliability now matters more than momentum bursts. Efficiency gains must convert into measurable results. Credible progress tends to compress risk premiums. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Dec. 27 at 9:14 AM
$ALT
0 · Reply
Muskvoice
Muskvoice Dec. 27 at 8:35 AM
$ALT
0 · Reply
Guptasulo
Guptasulo Dec. 27 at 7:50 AM
$ALT Here is another article freely accessible; https://www.sciencedirect.com/science/article/pii/S0146280625002324 Supplements "Didioh $ALT nytimes.com/2025/12/21/heal... Check this out. It talks about discontinuation of glp-1’s due to side effects and muscle loss." Reason why people are abandoning GLP-1 (others) which ALT now satisfies with Muscle preservation+ Liver issues that it solves see below; "ImNotLion $ALT Annual deaths in the US from liver conditions: 60,000 - 70,000 Europe: 200,000 - 250,000..."
0 · Reply
ImNotLion
ImNotLion Dec. 27 at 7:10 AM
$ALT Annual deaths in the US from liver conditions: 60,000 - 70,000 Europe: 200,000 - 250,000 Safety, side effects and tolerance have been satisfied. This would seem to justify fast tracking Pemvidutide in both. The bureaucracy of approvals needs to address this life saving drug ASAP. Even 10% of that total would be like a city population of fatalities due to lengthy delays. Inexcusable!
0 · Reply
Wolf1971
Wolf1971 Dec. 27 at 5:34 AM
$ALT
0 · Reply
Didioh
Didioh Dec. 27 at 5:07 AM
$ALT https://www.nytimes.com/2025/12/21/health/older-people-glp1-weight.html?smid=nytcore-ios-share Check this out. It talks about discontinuation of glp-1’s due to side effects and muscle loss. Hello Pemvi.
3 · Reply
BuddyBoy6975
BuddyBoy6975 Dec. 27 at 4:47 AM
$ALT My question HERE is what news are THESE buyers seeing…?
0 · Reply
BuddyBoy6975
BuddyBoy6975 Dec. 27 at 4:22 AM
$ALT So my take on my time here WS obviously sees the Gi-NORMOUS future rev’s in Alt’s pipeline/pemvi So THEY (always banks) have been suppressing SP so their CO-PARTIES can toss low ball offers at them via BO But ALT has said FU, we’re not gonna sell you US @ $50/share. You can pound sand. And that’s where we are JMO
1 · Reply
golfeveryday
golfeveryday Dec. 27 at 4:16 AM
$ALT it’s funny how everyone wanted good 48 week data and EOP2 meeting and Garg gone. Got all those things and now things are dire?
0 · Reply
Canuckforabuck
Canuckforabuck Dec. 27 at 3:55 AM
0 · Reply
Rolf1968
Rolf1968 Dec. 27 at 3:27 AM
$ALT
0 · Reply
Chop1182
Chop1182 Dec. 27 at 3:26 AM
$ALT monjourno needs to step aside and Make room for Pemvi! Too many ads for those with all my Pemvi searching/dd lol
0 · Reply
Funk49R
Funk49R Dec. 27 at 2:50 AM
$ALT Done
0 · Reply
Geohotventures
Geohotventures Dec. 27 at 2:43 AM
$ALT Jacked with another comprehensive piece on Reddit: https://www.reddit.com/r/Altimmune/s/9CmteofDlk
1 · Reply
Paul4321
Paul4321 Dec. 27 at 12:56 AM
$ALT Lots of bad or misinformed advice on this board on how much market manipulation SP comes into play when getting a deal done. If BP solely looked at SP when trying to get a partnership/BO deal done then no small biotech would ever get anywhere. BP first looks at clinical and scientific strength of the asset. Regulatory milestones matter hugely (FDA EOP2, BTD). Peer reviewed and presentations at top meetings (AASLD). Market opportunity and competitive landscape (total addressable market - obesity/MASH/ALD/AUD). Cost to completion (BTD/AA?), revenue potrntial, expected peak sales, and pricing and reimbursement prospects. Enough with the BOD needs to by this many shares each. We are past that point, and besides Durso and Gill gave you a hint which way the wind is blowing on EOP2 alignment without holding your hands. Anything more at this point might come under legal scrutiny. Your ignorance is my opportunity to buy more shares and very likely HFs/Banks/Tutes/MMs/and possible suitors
3 · Reply
daddyoco
daddyoco Dec. 27 at 12:33 AM
$ALT yes, he should stay on as adviser only is the way 2 go 4 sure
0 · Reply
Turribull
Turribull Dec. 27 at 12:26 AM
$ALT This molecule works and will be brought to market. Wheels are turning fast right now, even if the SP isn’t. My conviction is unmoved and my anticipation is high. Have a great weekend and remember, you don’t need to be honest to post here - just need a user name and password. 🤓👊🏻
1 · Reply
BigBALLS1111
BigBALLS1111 Dec. 27 at 12:25 AM
$ALT just came to the grave of bulls to remind this is turd 💩
0 · Reply
PharmXprt
PharmXprt Dec. 27 at 12:18 AM
$ALT Keeping Garg on as a board advisor through mid-2026 actually reinforces the view that ALT is being positioned for a strategic outcome rather than a pure go-it-alone strategy. Garg provides scientific continuity, historical context, and credibility for FDA interactions and partner due diligence, while Durso focuses on valuation, positioning, and transaction execution. This division of labor is common when boards shift from development execution to value optimization. Removing Garg entirely would raise unnecessary red flags with regulators and potential partners, while keeping him as CEO would better align with a long, dilution-heavy Phase 3 path. By keeping Garg in an advisory role only until mid-2026, ALT signals that a partnership or M&A transaction is highly possible before that timeframe, preserving institutional knowledge without committing to multi-year standalone execution.
1 · Reply
daddyoco
daddyoco Dec. 27 at 12:05 AM
$ALT on gargs way out, i hope durso blackens his eye with a bitch slap - get the fk out garg!
2 · Reply